18863
document
Creon 10,000 Minimicrospheres vs. Creon 8,000 microspheres -- an open randomised crossover preference study . Creon 10,000 Minimicrospherestrade mark ( Creon ) 10,000 MMS ) is a pancreatic enzyme formulation that contains smaller spheres of pancreatin in a 50 % smaller capsule than conventional microspheres ( Creon ) 8,000 ) . This three-centre study investigated the preference of cystic fibrosis ( CF ) patients for these products . In one centre , 72 h stool fat excretion and coefficient of fat absorption ( CFA ) were also compared . Fifty-nine patients with a mean age 10 years ( range 3-17 ) took Creon 8,000 ms for 14 days and were then randomised to 28 days of Creon 8,000 ms followed by 28 days of Creon 10,000 MMS , or vice versa . Dosing was lipase for lipase according to the labelled declaration . At the end of the second treatment period , 51 of 54 patients who completed the study expressed a preference , with a statistically significant preference in favour of Creon 10,000 MMS ( 47/51 ; 87 % ) vs. Creon 8,000 ms ( 4/51 ; 7.4 % ; P < 0.0001 ) . Stool fat ( g/day ) and CFA ( % ) were measured in 24 patients at the end of each treatment period : the products were therapeutically equivalent ( Creon 10,000 : 8.4 g/day , 91.3 % CFA ; Creon 8,000 : 6.7 g/day , 93.5 % CFA ) . Both products were well tolerated . In conclusion , in CF children we found a clear preference for Creon 10,000 MMS compared with Creon 8,000 ms with no difference in fat absorption between the two products . Creon 10,000s smaller capsules are easier to take and should aid patient compliance .
18864
Intervention_Pharmacological
Creon 10,000 Minimicrospheres
18865
Intervention_Pharmacological
Creon 8,000 microspheres
18866
Intervention_Pharmacological
Creon 10,000 Minimicrospherestrade mark ( Creon ) 10,000 MMS )
18867
Intervention_Pharmacological
microspheres ( Creon ) 8,000 )
18868
Intervention_Pharmacological
Creon 8,000 ms
18869
Intervention_Pharmacological
Creon 10,000 MMS
18870
Intervention_Pharmacological
Creon
18871
Intervention_Pharmacological
Creon
18872
Outcome_Other
preference
18873
Outcome_Physical
stool fat excretion
18874
Outcome_Physical
coefficient of fat absorption ( CFA )
18875
Outcome_Other
statistically significant preference
18876
Outcome_Physical
Stool fat ( g/day )
18877
Outcome_Physical
CFA ( % )
18878
Outcome_Physical
fat absorption
18879
Participant_Condition
cystic fibrosis ( CF )
18880
Participant_Sample-size
Fifty-nine
18881
Participant_Age
mean age 10 years ( range 3-17 )
18882
Participant_Sample-size
51 of 54
18883
Participant_Condition
CF
18884
Participant_Age
children